Chlorambucil – rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: A clinical and biological analysis

D. Laszlo Division of Hemato-Oncology, European Institute of Oncology, Milan, ItalyCorrespondence[email protected]

C. Rabascio Division of Hemato-Oncology, European Institute of Oncology, Milan, Italy

G. Andreola Division of Hemato-Oncology, European Institute of Oncology, Milan, Italy

G. Pruneri Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy

V. Raia Division of Hemato-Oncology, European Institute of Oncology, Milan, Italy

L. Calabrese Division of Hemato-Oncology, European Institute of Oncology, Milan, Italy

D. Radice Division of Statistical Analysis, European Institute of Oncology, Milan, Italy

L. Saronni Division of Hemato-Oncology, European Institute of Oncology, Milan, Italy

G. Martinelli Division of Hemato-Oncology, European Institute of Oncology, Milan, Italy

show all

"Chlorambucil – rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: A clinical and biological analysis." Leukemia & Lymphoma, 48(2), pp. 437–438

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Chlorambucil – rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: A clinical and biological analysis

Information for

Open access

Opportunities

Help and information

Chlorambucil – rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: A clinical and biological analysis

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature